Biology:Brainshuttle

From HandWiki
Short description: Technology assisting antibody uptake


Brainshuttle or brain shuttle is a technology developed to help molecules such as monoclonal antibodies to cross the blood-brain barrier more than they would otherwise. It has been tested with anti-amyloid monoclonal antibodies such as gantenerumab and trontinemab.[1][2][3][4][5][6]

References

  1. ↑ Ruderisch, Nadine; Schlatter, Daniel; Kuglstatter, Andreas; Guba, Wolfgang; Huber, Sylwia; Cusulin, Carlo; Benz, Jörg; Rufer, Arne Christian et al. (October 2017). [10.1016/j.ebiom.2017.09.004 "Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport"] (in en). eBioMedicine 24: 76–92. doi:10.1016/j.ebiom.2017.09.004. PMC 5652008. 10.1016/j.ebiom.2017.09.004. 
  2. ↑ Morito, Takahiro; Harada, Ryuichi; Iwata, Ren; Du, Yiqing; Okamura, Nobuyuki; Kudo, Yukitsuka; Yanai, Kazuhiko (28 January 2021). "Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody" (in en). Scientific Reports 11 (1): 2588. doi:10.1038/s41598-021-82037-2. ISSN 2045-2322. PMC 7844286. https://www.nature.com/articles/s41598-021-82037-2. 
  3. ↑ Campos, Christopher R.; Kemble, Alicia M.; Niewoehner, Jens; Freskgård, Per-Ola; Urich, Eduard (10 March 2020). "Brain Shuttle Neprilysin reduces central Amyloid-β levels" (in en). PLOS ONE 15 (3): e0229850. doi:10.1371/journal.pone.0229850. ISSN 1932-6203. 
  4. ↑ Hultqvist, Greta; Syvänen, Stina; Fang, Xiaotian T.; Lannfelt, Lars; Sehlin, Dag (2017). "Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor" (in en). Theranostics 7 (2): 308–318. doi:10.7150/thno.17155. PMID 28042336. 
  5. ↑ Grimm, Hans Peter; Schumacher, Vanessa; Schäfer, Martin; Imhof-Jung, Sabine; Freskgård, Per-Ola; Brady, Kevin; Hofmann, Carsten; Rüger, Petra et al. (2023). "Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans". mAbs 15 (1): 2261509. doi:10.1080/19420862.2023.2261509. ISSN 1942-0870. PMID 37823690. 
  6. ↑ Kulic, Luka; Vogt, Annamarie; Alcaraz, Fabien; Barrington, Philip; Marchesi, Maddalena; Klein, Gregory; Croney, Ruth; Agnew, David et al. (1 September 2022). "053 Brainshuttle AD: Investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD" (in en). Journal of Neurology, Neurosurgery & Psychiatry 93 (9): e2. doi:10.1136/jnnp-2022-abn2.97. ISSN 0022-3050. https://jnnp.bmj.com/content/93/9/e2.249. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Brainshuttle&oldid=3546021"